Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-60

I recall you mentioning intrathecal administration a couple years ago. Is this something Race have kept in mind while developing the new formulation?

Maybe this isn't a relevant question now, but possibly interesting. Unless I misunderstood, your comment back then alluded to bisantrene possibly crossing a leaky BBB without being administered intrathecally. Assuming I read that right, are there different levels of severity in a leaky BBB that would change required dosing? Is it a strategy that is employed with other drugs where a framework could be referenced?